Emerging Topical and Systemic JAK Inhibitors in Dermatology
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders. Here, the elucidation of key pathogenic factors such as IL...
Main Authors: | Farzan Solimani, Katharina Meier, Kamran Ghoreschi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-12-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.02847/full |
Similar Items
-
The role of janus kinases in the treatment of autoimmune skin diseases
by: Arnold Kukowka, et al.
Published: (2021-02-01) -
Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis
by: Ronan Talty, BS, et al.
Published: (2021-10-01) -
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
by: Srdan Verstovsek, et al.
Published: (2017-02-01) -
Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates
by: Adriana Coricello, et al.
Published: (2020-07-01) -
A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
by: Dillon KAL
Published: (2021-06-01)